Breaking News Instant updates and real-time market news.

CLSD

Clearside Biomedical

$1.10

0.03 (2.80%)

07:07
07/09/19
07/09
07:07
07/09/19
07:07

Clearside Biomedical enters license agreement with Aura Biosciences

Clearside Biomedical announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside's Suprachoroidal Space Microinjectorto deliver Aura's proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma. Aura is developing a novel class of therapies, viral nanoparticle conjugates, designed to selectively bind and eliminate cancer cells without damaging surrounding normal tissues. Aura is licensing Clearside's proprietary SCS Microinjector as a potential non-surgical alternative to intravitreal delivery of Aura's proprietary anti-cancer drug candidates, which may enable the delivery of higher concentrations using a lower dose to the choroid and adjacent areas. If the collaboration proves successful following preclinical and proof-of-concept studies, Aura may utilize the SCS Microinjector for certain future development programs. Pursuant to the licensing agreement, Clearside is eligible to receive payments related to pre-specified development, regulatory and sales milestones, as well as royalties on product sales that utilize the SCS Microinjector.

  • 19

    Oct

CLSD Clearside Biomedical
$1.10

0.03 (2.80%)

11/05/18
JPMS
11/05/18
DOWNGRADE
Target $8
JPMS
Underweight
JPMorgan double downgrades Clearside to Underweight on study failure
JPMorgan analyst Anupam Rama double downgraded Clearside Biomedical to Underweight from Overweight and lowered his price target for the shares to $8 from $16. The stock in early trading is down 56%, or $3.12, to $2.44. The analyst also removed Clearside from his firm's Analyst Focus List. The company this morning announced that the Phase 3 Sapphire results for Xipere plus Eylea in retinal vein occlusion did not meet the primary endpoint of third-line gainers versus Eylea alone, Rama tells investors in a research note. The results are "clearly disappointing," says Rama. The analyst sees no material value creation catalysts on the horizon and believes the overall negative sentiment on shares is unlikely to change until the company is closer to approval/commercialization.
11/05/18
COWN
11/05/18
DOWNGRADE
COWN
Market Perform
Clearside Biomedical downgraded earlier to Market Perform at Cowen
11/05/18
STFL
11/05/18
DOWNGRADE
Target $4
STFL
Hold
Clearside Biomedical downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy earlier downgraded Clearside Biomedical to Hold from Buy following the failure of the SAPPHIRE trial in RVO and subsequent discontinuation of the program. Clearside's value now depends primarily on the success of Xipere for the treatment of macular edema associated with non-infectious uveitis, said Samimy, who lowered her price target on the stock to $4 from $20. The SAPPHIRE failure also has implications for the future clinical design for DME, since "designing it as a superiority trial appears off the table now," Samimy believes.
11/06/18
NEED
11/06/18
NO CHANGE
Target $4
NEED
Buy
Clearside Biomedical price target lowered to $4 from $22 at Needham
Needham analyst Serge Belanger lowered his price target on Clearside Biomedical to $4 after its announcement yesterday that the Sapphire Phase 3 study evaluating Xipere in RVO patients did not meet its primary endpoint. The analyst also keeps his Buy rating, stating that while Clearside Biomedical is discontinuing the clinical development of its RVO program, it will remain focused on the Xipere opportunity in uveitis. Belanger adds that the valuation on the shares is now below cash levels and fails to capture the uveitis opportunity with potential peak sales of as high as $150M.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$362.50

-3.22 (-0.88%)

05:54
07/18/19
07/18
05:54
07/18/19
05:54
Recommendations
Netflix analyst commentary  »

Netflix earnings selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$39.03

-0.87 (-2.18%)

05:50
07/18/19
07/18
05:50
07/18/19
05:50
Recommendations
eBay analyst commentary  »

eBay price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$49.68

0.04 (0.08%)

05:48
07/18/19
07/18
05:48
07/18/19
05:48
Earnings
BB&T reports Q2 EPS $1.09, consensus $1.07 »

Reports Q2 revenue $3.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Jul

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

APD

Air Products

$226.47

-0.59 (-0.26%)

05:47
07/18/19
07/18
05:47
07/18/19
05:47
Downgrade
Air Products rating change  »

Air Products downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 22

    Aug

SENS

Senseonics

$1.30

-0.38 (-22.69%)

05:46
07/18/19
07/18
05:46
07/18/19
05:46
Earnings
Senseonics 22.727M share Secondary priced at $1.10 »

Jefferies LLC is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Sep

  • 18

    Jul

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

, AAPL

Apple

$203.32

-1.08 (-0.53%)

05:45
07/18/19
07/18
05:45
07/18/19
05:45
Downgrade
Skyworks, Apple rating change  »

Barclays downgrades…

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

AAPL

Apple

$203.32

-1.08 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

LBTYA

Liberty Global

$26.00

-0.11 (-0.42%)

, VOD

Vodafone

$15.68

-0.07 (-0.44%)

05:44
07/18/19
07/18
05:44
07/18/19
05:44
Hot Stocks
Liberty Global sale of certain EU operations to Vodafone approved by EC »

The European Commission,…

LBTYA

Liberty Global

$26.00

-0.11 (-0.42%)

VOD

Vodafone

$15.68

-0.07 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

QCOM

Qualcomm

$75.75

0.09 (0.12%)

05:42
07/18/19
07/18
05:42
07/18/19
05:42
Downgrade
Qualcomm rating change  »

Barclays downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

SBNY

Signature Bank

$124.89

-0.41 (-0.33%)

05:42
07/18/19
07/18
05:42
07/18/19
05:42
Earnings
Signature Bank reports Q2 EPS $2.72, consensus $2.71 »

Reports Q2 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AGN

Allergan

$162.57

-1.69 (-1.03%)

, ABBV

AbbVie

$68.32

-0.82 (-1.19%)

05:39
07/18/19
07/18
05:39
07/18/19
05:39
Downgrade
Allergan, AbbVie rating change  »

Allergan downgraded to…

AGN

Allergan

$162.57

-1.69 (-1.03%)

ABBV

AbbVie

$68.32

-0.82 (-1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

SAP

SAP

$134.22

-0.9 (-0.67%)

05:39
07/18/19
07/18
05:39
07/18/19
05:39
Earnings
SAP expects FY19 revenue to 'increase strongly' »

Backs FY19 cloud revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 01

    Aug

SAP

SAP

$134.22

-0.9 (-0.67%)

05:33
07/18/19
07/18
05:33
07/18/19
05:33
Earnings
SAP reports Q2 non-IFRS EPS EUR 1.09 vs. EUR 0.98 last year »

Reports Q2 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 01

    Aug

CMA

Comerica

$69.23

-2.52 (-3.51%)

05:26
07/18/19
07/18
05:26
07/18/19
05:26
Downgrade
Comerica rating change  »

Comerica downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

EBAY

eBay

$39.03

-0.87 (-2.18%)

05:26
07/18/19
07/18
05:26
07/18/19
05:26
Recommendations
eBay analyst commentary  »

eBay price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.50

-3.22 (-0.88%)

05:23
07/18/19
07/18
05:23
07/18/19
05:23
Recommendations
Netflix analyst commentary  »

Netflix content lineup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$217.73

12.67 (6.18%)

05:20
07/18/19
07/18
05:20
07/18/19
05:20
Downgrade
ASML rating change  »

ASML downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$90.11

0.99 (1.11%)

05:20
07/18/19
07/18
05:20
07/18/19
05:20
Earnings
Novartis raises FY19 revenue view to up mid to high-single digit »

Novartis provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

05:18
07/18/19
07/18
05:18
07/18/19
05:18
Upgrade
Skyworks rating change  »

Skyworks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$203.32

-1.08 (-0.53%)

05:18
07/18/19
07/18
05:18
07/18/19
05:18
Upgrade
Apple rating change  »

Apple upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

05:16
07/18/19
07/18
05:16
07/18/19
05:16
Downgrade
Skyworks rating change  »

Skyworks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$75.75

0.09 (0.12%)

05:15
07/18/19
07/18
05:15
07/18/19
05:15
Downgrade
Qualcomm rating change  »

Qualcomm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

VET

Vermilion Energy

$21.12

-0.44 (-2.04%)

05:14
07/18/19
07/18
05:14
07/18/19
05:14
Downgrade
Vermilion Energy rating change  »

Vermilion Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

XOM

Exxon Mobil

$75.49

-0.44 (-0.58%)

05:13
07/18/19
07/18
05:13
07/18/19
05:13
Downgrade
Exxon Mobil rating change  »

Exxon Mobil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TTD

Trade Desk

$244.23

0.72 (0.30%)

05:12
07/18/19
07/18
05:12
07/18/19
05:12
Downgrade
Trade Desk rating change  »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$90.11

0.99 (1.11%)

05:11
07/18/19
07/18
05:11
07/18/19
05:11
Earnings
Novartis reports Q2 core EPS $1.34, consensus $1.22 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.